GlassScriptPhysician profile
Martha Ellen Serven
NPI 1144299850
$1,102.67
in general payments reported to CMS, 2019-2025
15 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.19 · 2022: $271 · 2023: $275 · 2024: $126 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718 · Consulting Fee: $22.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.78 |
| Consulting Fee | $22.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $244.31 | 2021-2025 | Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $200.81 | 2023-2025 | Takhzyro, Cuvitru |
| Genzyme Corporation | $154.28 | 2024-2025 | |
| Viiv Healthcare Company | $122.36 | 2022 | |
| Blueprint Medicines Corporation | $107.52 | 2023 | Ayvakit |
| Biocryst US Sales Co., LLC | $54.79 | 2022-2024 | Orladeyo |
| Pfizer INC. | $43.51 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $30.64 | 2025 | Dupixent |
| Incyte Corporation | $26.56 | 2024 | Opzelura |
| Genentech USA, INC. | $25.76 | 2024 | Xolair |
| Pharming Healthcare, INC. | $25.43 | 2025 | Ruconest |
| Adma Biomanufacturing LLC | $22.94 | 2025 | |
| Csl Behring | $15.16 | 2025 | Hizentra |
| Amgen INC. | $14.87 | 2025 | Tezspire |
| Glaxosmithkline, LLC. | $13.73 | 2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Serven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.